Lucinda Quan
Fundador en ALIGOS THERAPEUTICS, INC. .
Fortuna: 314 770 $ al 30/04/2024
Cargos activos de Lucinda Quan
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Fundador | 05/02/2018 | - |
| Consejero General | 01/03/2018 | - |
Historial de carrera de Lucinda Quan
Antiguos cargos conocidos de Lucinda Quan.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2016 | 01/04/2018 |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Consejero General | 01/11/2013 | 01/01/2016 |
| INTERMUNE INC | Consejero General | 01/09/2004 | 01/11/2013 |
Formación de Lucinda Quan.
| University of California, Los Angeles | Graduate Degree |
Estadísticas
Internacional
| Estados Unidos | 6 |
Operativa
| General Counsel | 3 |
| Founder | 1 |
| Graduate Degree | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Lucinda Quan
- Experiencia